Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD

Respirology

Volumn 21, Issue 7, 2016, Pages 1235-1242

  Rodrigo Troyano, Ana ^a,b   Suarez Cuartin, Guillermo ^a,b   Peiró, Meritxell ^a,b   Barril, Silvia ^a,b   Castillo, Diego ^a,b   Sanchez Reus, Ferran ^b,c   Plaza, Vicente ^a,b   Restrepo, Marcos I ^d   Chalmers, James D ^e   Sibila, Oriol ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

COPD; exacerbation; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID;

ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE; AGED; ALCOHOL CONSUMPTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BRONCHIECTASIS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SMOKING; SPAIN; SPUTUM CULTURE; TERTIARY CARE CENTER;

EID: 84987654222     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12825     Document Type: Article

References (40)

1. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am.J.Respir.Crit Care Med. 2006; 173: 1114–21.
2. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117: 380S–5.
3. Groenewegen KH, Wouters EF. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir. Med. 2003; 97: 770–7.
4. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 1995; 152: 1316–20.
5. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 853–60.
6. Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007; 12: 81–7.
7. Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 2009; 15: 138–42.
8. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 1999; 43: 1379–82.
9. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 2002; 34: 634–40.
10. Lipovy B, Rihova H, Hanslianova M, Gregorova N, Suchanek I, Brychta P. Prevalence and resistance of Pseudomonas aeruginosa in severely burned patients: a 10-year retrospective study. Acta Chir. Plast. 2010; 52: 39–43.
11. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob.Agents Chemother. 2006; 50: 43–8.
12. Joo EJ, Kang CI, Ha YE, Kang SJ, Park SY, Chung DR, Peck KR, Lee NY, Song JH. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb. Drug Resist. 2011; 17: 305–12.
13. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb. Drug Resist. 2005; 11: 68–74.
14. Morata L, Cobos-Trigueros N, Martinez JA, Soriano A, Almela M, Marco F, Sterzik H, Nunez R, Hernandez C, Mensa J. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 2012; 56: 4833–7.
15. Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, Antonelli M, Welte T, Clair B, Ostermann H et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit. Care 2015; 19: 219–27.
16. Montero M, Dominguez M, Orozco-Levi M, Salvado M, Knobel H. Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study. Infection 2009; 37: 16–9.
17. Renom F, Yanez A, Garau M, Rubi M, Centeno MJ, Gorriz MT, Medinas M, Ramis F, Soriano JB, Alvar A. Prognosis of COPD patients requiring frequent hospitalization: role of airway infection. Respir. Med. 2010; 104: 840–8.
18. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 8487–92.
19. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187: 347–65.
20. Elborn JS, De Soyza A. COPD-bronchiectasis overlap syndrome. Eur. Respir. J. 2015; 45: 310–3.
21. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
22. Bartlett RC, 1974. Medical Microbiology: Quality Costs and Clinical Relevance. John Wiley & Sons, Inc. New York, N.Y.
23. Sharp S. Controversies in the performance of wound cultures. University of Texas Health Science Center Teleconference, Houston, Texas, 2004.
24. Garcia-Bellmunt L, Sibila O, Solanes I, Sanchez-Reus F, Plaza V. Pulmonary nocardiosis in patients with COPD: characteristics and prognostic factors. Arch. Bronconeumol. 2012; 48: 280–5.
25. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement M100-S23. Wayne, PA, USA: CLSI; 2013.
26. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012; 18: 268–81.
27. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin. Infect. Dis. 2008; 47(Suppl 1): S3–13.
28. Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, Xaubet A, Rodriguez-Roisin R, Torres A. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15–9.
29. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 2002; 34: 91–100.
30. Garcia-Vidal C, Almagro P, Romani V, Rodriguez-Carballeira M, Cuchi E, Canales L, Blasco D, Heredia JL, Garau J. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur. Respir. J. 2009; 34: 1072–8.
31. Almagro P, Salvado M, Garcia-Vidal C, Rodriguez-Carballeira M, Cuchi E, Torres J, Heredia JL. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012; 84: 36–43.
32. Garcia-Rodriguez JA, Casal M, Rodriguez F. Trends in antimicrobial resistance of Pseudomonas aeruginosa, Escherichia coli and Bacteroides fragilis (1997–2001). Rev. Esp. Quimioter. 2003; 16: 421–7.
33. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 1988; 16: 128–40.
34. Lode H, Allewelt M, Balk S, De Roux A, Mauch H, Niederman M, Schmidt-Ioanas M. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143–9.
35. Gallego M, Pomares X, Espasa M, Castaner E, Sole M, Suarez D, Monso E, Monton C. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC. Pulm. Med 2014; 14: 103–15.
36. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 2006; 9: 461–5.
37. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740–3.
38. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, Molin S. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat. Rev. Microbiol. 2012; 10: 841–51.
39. Dickson RP, Martinez FJ, Huffnagle GB. The role of microbiome in exacerbations of chronic lung diseases. Lancet 2014; 384: 691–702.
40. Domenech A, Puig C, Marti S, Santos S, Fernandez A, Calatayud L, Dorca J, Ardanuy C, Linares J. Infectious etiology of acute exacerbations in severe COPD patients. J.Infect. 2013; 67: 516–23.